Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from BB Biotech ( (CH:BION) ) is now available.
In Q2 2025, BB Biotech outperformed the Nasdaq Biotech Index, with a 10.2% increase in stock price in USD, despite a net loss of CHF 100 million due to exchange rate impacts. The company saw significant progress in its portfolio, with clinical and regulatory successes and strategic investments, including Sanofi’s acquisition offer for Blueprint Medicines, highlighting its innovation strategy and market resilience.
The most recent analyst rating on (CH:BION) stock is a Buy with a CHF66.00 price target. To see the full list of analyst forecasts on BB Biotech stock, see the CH:BION Stock Forecast page.
More about BB Biotech
BB Biotech is an investment company focused on the biotechnology sector, investing in a portfolio of companies with strong scientific and commercial potential. The company emphasizes innovation in the healthcare industry, particularly in areas like neurology, cardiology, and infectious diseases.
Average Trading Volume: 77,858
Technical Sentiment Signal: Sell
Current Market Cap: CHF1.76B
Learn more about BION stock on TipRanks’ Stock Analysis page.